(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Mystery foot suggests a second early human relative lived alongside Lucy - 25 Signs Now is the ideal time to Update Your Android Telephone: When to Take the Action
- 3New subclade K flu strain raises concerns: What families should know
- 4Toyota Motor Europe to roll out smart EV charging through new partnerships
- 5Pat Finn, actor from 'The Middle,' dies at 60 after bladder cancer diagnosis
- Top 15 Style Creators Changing the Business
- Single women risk rape and exploitation in search for better life in Europe
- Outside Lovers' Decision: Favored Climbing Rucksacks
- The ‘Stranger Things’ finale, explained: What happens to Vecna? And why was a key character’s fate left unknown?
- Vote in favor of the Top Vegetable for Senior
- As reefs vanish, assisted coral fertilization offers hope in the Dominican Republic
- 5 VIP Voice Exhibitions in Energized Movies
- Midlife weight gain can start long before menopause – but you can take steps early on to help your body weather the hormonal shift
- What to know as New York City nurses strike for a 3rd day
